Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy in Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria

• Life expectancy of at least 3 months.
• Diagnosed with Stage IV non-small cell lung cancer (NSCLC) without certain genetic changes.
• No previous treatment for metastatic NSCLC.
• Cancer must be measurable by standard criteria.
• Good overall health with a performance status score of 0 or 1.
• Adequate organ function as determined by medical tests.

Exclusion Criteria

• Have a mix of small-cell and non-small cell lung cancer.
• Pregnant, breastfeeding, or planning to breastfeed during the study.
• Previous treatment with certain immune-targeting drugs.
• Allergic to the study drugs or their ingredients.
• Have another active cancer or had one in the last 3 years.
• Have an active autoimmune disease needing treatment in the past 2 years.
• Taking long-term steroids.
• Have significant fluid retention in the body.
• Have untreated cancer spread to the brain or spinal cord.
• Have active inflammatory bowel disease or recent gastrointestinal perforation.
• Have a history of lung inflammation needing steroids.
• Have had a tissue or organ transplant.
• Received a live-virus vaccine within 30 days before starting treatment.
• Have active hepatitis B or C infection.